Oczyesa (Octreotide)

Octreotide, the active ingredient in Oczyesa, is a somatostatin analog presented as a subcutaneous formulation for subcutaneous use. It treats acromegaly and neuroendocrine tumor‑related conditions in adult patients. GNH USA supplies Oczyesa as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Octreotide is used to manage conditions related to excess hormone secretion and neuroendocrine tumor activity.

Acromegaly: reduces growth hormone levels and controls disease symptoms. Neuroendocrine tumors: inhibits secretion of vasoactive peptides and helps control tumor‑related symptoms. Carcinoid syndrome: decreases flushing and diarrhea by reducing serotonin release.

Common Side Effects: - Injection site reactions: pain, erythema, or swelling at the injection site. - Nausea and vomiting. - Diarrhea or abdominal cramping. - Hyperglycemia or altered glucose tolerance. - Fatigue or headache. - Gallbladder sludge or mild gallstone formation.

Serious or Rare Side Effects: - Acute pancreatitis. - Severe hypoglycemia, especially in diabetic patients. - Symptomatic gallstone disease or cholecystitis. - Cardiac arrhythmias or conduction abnormalities. - Anaphylactic or severe allergic reactions. - Acute renal impairment or failure.

Octreotide requires careful monitoring and specific handling precautions.

Monitor glucose levels: assess for hyper‑ or hypoglycemia during therapy. Assess gallbladder health: watch for gallstone formation or biliary colic. Evaluate cardiac function: consider baseline ECG in patients with cardiac risk. Adjust dose in renal/hepatic impairment: use lower doses or extended intervals as needed. Avoid in known hypersensitivity: discontinue if allergic reaction occurs. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Octreotide may interact with several medications, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Concomitant cyclosporine: increased risk of hyperglycemia. - Octreotide plus quinidine: may raise quinidine plasma concentrations. - Octreotide with insulin: can mask hypoglycemia symptoms.

Moderate Interactions (Monitor Closely): - Oral contraceptives: reduced efficacy due to hormone suppression. - Glucagon therapy: diminished glucagon effect. - Other peptide hormones: altered plasma levels and activity.